Marginal Zone Lymphoma (MZL): Oncology Hour

Watch Marginal Zone Lymphoma (MZL): Oncology Hour with expert oncologist Dr. Mayur Narkhede. Dr. Narkhede specializes in the treatment of non-Hodgkin’s lymphoma (NHL) and is board-certified in Internal Medicine, Hematology, and Medical Oncology. The live discussion was hosted by Massive Bio Patient Advocate Syeda Hasan. 

Marginal Zone Lymphoma (MZL): Oncology Hour covered topics including: 

• MZL and how common is it compared to other lymphomas 
• Symptoms and diagnosis of MZL  
• Treatment options and the standard of care for patients with MZL 
• Biomarkers for MZL 
• Clinical trials for MZL 

Submit the form on this page to watch the full event video. To attend more free events in the future, visit the Massive Bio Facebook page.  

Marginal zone lymphoma (MZL) is a group of slow growing B-cell lymphomas, which account for approximately eight percent of all non-Hodgkin’s lymphoma cases. The average age at diagnosis is 60. 

Clinical trials test scientific advancements in cancer treatment for cancers of all types with biomarkers identified in genomic testing. Patients who choose to enroll in trials can receive cutting-edge treatments such as targeted therapies and high-quality care under the direction of scientists, doctors, and researchers. Cancer patients might gain access to promising drugs and innovative treatments long before they’re made available to the public.  

Fill out the form and watch Marginal Zone Lymphoma (MZL): Oncology Hour, which aired on May 24th,  to learn about lymphoma clinical trials, MZL treatment options, how Massive Bio can help cancer patients, and more!